==== Front JGH Open JGH Open 10.1002/(ISSN)2397-9070 JGH3 JGH Open: An Open Access Journal of Gastroenterology and Hepatology 2397-9070 Wiley Publishing Asia Pty Ltd Melbourne 10.1002/jgh3.12423 JGH312423 Original Article Original Articles Sarcoidosis is associated with lower risks of penetrating disease and colectomy in hospitalized patients with inflammatory bowel disease Sarcoidosis and inflammatory bowel diseaseY Jiang et al.Jiang Yi https://orcid.org/0000-0001-5114-0183 1 yi.jiang@rutgers.edu Rim Daniel S 1 Rodgers Brandon 1 Ahlawat Sushil 2 1 Department of Medicine Rutgers New Jersey Medical School Newark New Jersey USA 2 Division of Gastroenterology and Hepatology Rutgers New Jersey Medical School Newark New Jersey USA * Correspondence Yi Jiang, Department of Medicine, Rutgers New Jersey Medical School, 150 Bergen Street, UH I‐248, Newark, NJ 07101, USA. Email: yi.jiang@rutgers.edu 05 10 2020 12 2020 4 6 10.1002/jgh3.v4.61199 1206 03 3 2020 20 9 2020 © 2020 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Abstract Background and Aim Inflammatory bowel disease (IBD) and sarcoidosis, primarily considered distinct entities, share commonalties in pathophysiology and clinical manifestations. This study aimed to examine the in‐hospital outcomes of patients with concurrent IBD and sarcoidosis. Methods The National Inpatient Sample was used to identify hospitalized adult patients with IBD and sarcoidosis from 2010 to 2014. Primary outcomes were in‐hospital mortality, rates of septic shock, acute renal failure, respiratory failure, length of stay, and total hospitalization charges. Secondary outcomes were IBD‐specific complications and surgery interventions. Results A total of 3995 patients with IBD and coexisting sarcoidosis (IBD/sarcoidosis), of which 2500 patients had Crohn's disease with coexisting sarcoidosis (Crohn's disease [CD]/sarcoidosis) and 1495 patients had ulcerative colitis with coexisting sarcoidosis (ulcerative colitis [UC]/sarcoidosis), were included. Patients with IBD/sarcoidosis had a lower risk of penetrating disease (adjusted odds ratio [aOR] 0.3, 95% confidence interval [CI] 0.16–0.55, P < 0.0001) and colectomy (aOR 0.48, 95% CI 0.27–0.84, P < 0.05). Subgroup analysis demonstrated lower rates of colectomy when comparing CD/sarcoidosis (P < 0.05) and UC/sarcoidosis (P = 0.0003) versus CD or UC alone. There was no difference in mortality. Conclusion IBD/sarcoidosis is associated with lower risks of penetrating disease and colectomy when compared to patients with IBD alone. Sarcoidosis is associated with a lower rate of penetrating disease, leading to less colectomy in patients hospitalized with Crohn's disease and a higher rate of respiratory failure but a lower rate of colectomy in patients hospitalized with ulcerative colitis. colectomyinflammatory bowel diseasepenetrating diseasesarcoidosis source-schema-version-number2.0cover-dateDecember 2020details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:5.9.5 mode:remove_FC converted:11.12.2020 Declaration of conflict of interest: The authors confirm that there are no known conflicts of interest associated with this publication. ==== Body Introduction Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease (CD), and sarcoidosis are multifactorial disorders resulting from a complex interplay between genetic predisposition and environmental influence. 1 , 2 , 3 , 4 Although usually considered to be distinct entities, they share similar clinical and histopathological presentations. The underlying pathological changes in each disease result in the formation of granulomas 5 , 6 with resulting clinical overlap of ocular, dermatologic, and joint manifestations. 7 , 8 , 9 Furthermore, patients with IBD can present with pulmonary disease, 5 , 6 and similar inflammatory changes that occur in the bowel and airway have been reported. 10 Similarly, clinically recognizable gastrointestinal involvement has been observed in patients with sarcoidosis. 11 , 12 In fact, increasing amounts of immunological, bacteriological, and genetic data have supported a link between IBD and sarcoidosis. 13 Observational studies first demonstrated nearly 50% positivity of Kveim testing in CD patients in the 1970s, 14 which suggested a shared mechanism between CD and sarcoidosis. Since that initial study, a large amount of evidence has emerged, such as elevations of CD4/CD8 lymphocyte ratios in bronchoalveolar lavage fluid seen in both CD and sarcoidosis, 15 , 16 , 17 as well as similar signs of response to mycobacterial infection in CD 18 and sarcoidosis tissues. 19 Concurrence of sarcoidosis and UC has also been previously reported. In addition, their pathogenic and immunogenic associations were suggested by several studies. 20 , 21 , 22 , 23 A nationwide Danish study also found a significantly increased risk of sarcoidosis in the population of patients with a diagnosis of UC or CD. 24 Genome‐wide association studies have also found that IBD and sarcoidosis share susceptibility loci. 25 , 26 , 27 Despite the tremendous progress in our understanding of the link or potential overlap of IBD and sarcoidosis, little is known regarding their clinical correlation. To date, there have been no large nationally representative studies to clarify the clinical outcomes in patients with coexisting IBD and sarcoidosis. In this nationwide study, we aimed to examine the outcomes (including length of stay [LOS], total hospitalization charges, in‐hospital mortality, and complications) for patients admitted with IBD who had coexisting sarcoidosis. Specifically, we investigated the disease‐/hospitalization‐related complications and their interventions, which can represent IBD severity 28 , 29 , 30 in this patient population. Methods Data source We obtained data from the Nationwide Inpatient Sample (NIS) database, which is the largest all‐payer inpatient care database in the United States. It is designed to approximate a 20% sample of the U.S. community hospitals. Yearly sampling weights are applied to generate national estimates. 31 This database has been used previously to provide reliable estimate burdens of IBD 32 and sarcoidosis. 33 The data include demographic information (age, gender, and race); hospital information (bed size and teaching status); insurance status; discharge disposition; diagnoses and procedures identified by The International Classification of Diseases‐Ninth Edition Revision, Clinical Modification (ICD‐9 CM) codes; total hospital charges; and LOS. Study population Our study was a retrospective cohort study of adult (18–90 years old) patients hospitalized with coexisting diagnosis codes for IBD (either CD or UC, ICD‐9 CM codes: 555.x and 556.x, respectively) and sarcoidosis (ICD‐9 CM code: 135) in the United States from 2010 to 2014. The control group was all IBD patients without a diagnosis of sarcoidosis (IBD alone group). Subgroup analysis was performed to compare coexisting CD and sarcoidosis versus CD alone, as well as coexisting UC and sarcoidosis versus UC alone. Demographic and clinical characteristics were collected (Table 1). Elixhauser Comorbidity Index 34 (ECI), which measures 29 common medical conditions and assigns different weights to compile a score, was used to analyze the severity of comorbidities. Procedures and interventions during hospitalization, such as mechanical ventilation (MV), prolonged MV (more than 96 h MV), total parental nutrition (TPN), and central venous catheterization (CVC), were also included. All ICD‐9 CM codes are provided in Table S1, Supporting information. Table 1 Comparison of selected variables of patients hospitalized with inflammatory bowel disease (IBD) with and without coexisting sarcoidosis Variable IBD with sarcoidosis IBD without sarcoidosis P‐value N (weighted) n = 3995 n = 3995 Age 54.5 ± 0.6 55.4 ± 0.2 0.29 ECI score 5 ± 0.4 5.1 ± 0.1 0.88 Length of stay (days) 5.9 ± 0.3 5.5 ± 0.2 0.25 Total hospitalization charges (dollars) 48 338.3 ± 3204.2 42 621.7 ± 2529 0.15 Female 2590 (64.8) 2490 (62.3) 0.34 Caucasian 2420 (60.6) 2465 (61.7) 0.47 Large hospital bed 2535 (63.5) 2635 (66) 0.54 Urban teaching hospital 2350 (58.8) 2500 (62.6) 0.058 Medicare 1765 (44.2) 1910 (47.8) 0.68 Routine disposition 2730 (68.4) 2690 (67.3) 0.68 Mechanical ventilation 235 (5.9) 180 (4.5) 0.23 Prolonged mechanical ventilation 40 (1) 65 (1.6) 0.24 Total parenteral nutrition 135 (3.4) 150 (3.8) 0.69 Central venous catheterization 165 (4.1) 165 (4.1) 1.00 In‐hospital mortality 55 (1.4) 80 (2) 0.34 Septic shock 95 (2.4) 100 (2.5) 0.86 Acute renal failure 530 (13.3) 555 (13.9) 0.69 Respiratory failure 325 (8.1) 180 (4.5) 0.0033 Malnutrition 165 (4.1) 225 (5.6) 0.15 Penetrating disease 70 (1.8) 225 (5.6) <0.0001 Stricturing disease/bowel obstruction 265 (6.6) 350 (8.8) 0.09 Colectomy 95 (2.4) 195 (4.9) 0.0067 Ileostomy 50 (1.3) 95 (2.4) 0.09 Values were reported as weighted means ± standard errors and weighted numbers (%). ECI, Elixhauser Comorbidity Index. The primary outcomes were in‐hospital outcomes, including mortality, septic shock, acute renal failure, respiratory failure, LOS, and total hospitalization charges. Our secondary outcomes included the IBD‐specific outcomes, including known complications of IBD such as malnutrition, penetrating disease, stricturing disease/bowel obstruction, and surgical interventions such as colectomy and ileostomy. Statistics SAS Survey Procedures (SAS 9.4, SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses. The propensity scoring method 35 , 36 was used to select the control group (IBD patients without coexisting sarcoidosis) in order to mitigate selection bias and to control for patient and institutional imbalances. The scoring was based on a multivariate logistic regression model accounting for age, gender, race, primary insurance payer, hospital type, hospital bed size, hospital region, and hospital teaching status. Using an 8‐to‐1‐digit match, we paired each admission in the IBD coexisting sarcoidosis group with one admission in the IBD without sarcoidosis group. The national estimates were calculated after accounting for the sample design elements (clusters, strata, and trend weights) provided by the NIS. Continuous variables were reported as weighted means ± standard errors (SEs), and categorical variables were reported as weighted numbers (N) and percentages (%). The SEs of weighted means were estimated by using the Taylor linearization method that incorporates the sample design. The Rao‐Scott‐modified chi‐square test was used to test the difference in distribution for categorical variables, while a weighted Student's t‐test was used to analyze the normally distributed continuous variables. Variables that are not normally distributed were tested by the Wilcoxon rank‐sum tests. A multivariate logistic regression was used to estimate the odds ratio of in‐hospital mortality, septic shock, acute renal failure, respiratory failure, IBD complications, and surgical interventions. Confounders included in the regression analysis were patient demographics, hospital bed size, hospital location/teaching status, insurance type, median household income, and ECI score. In addition, a multivariate linear regression was used to estimate the average change in LOS and total hospital charges after adjusting for the same covariates described above. Results Patient characteristics In this study, a total of 302 105 patients were admitted for IBD, of which 192 290 patients had CD and 109 815 patients had UC. A total of 3995 IBD patients were diagnosed with coexisting sarcoidosis (IBD/sarcoidosis), of which 2500 patients had CD coexisting with sarcoidosis (CD/sarcoidosis) and 1495 patients had UC coexisting with sarcoidosis (UC/sarcoidosis). After matching, the IBD/sarcoidosis, CD/sarcoidosis, and UC/sarcoidosis groups were compared to equal numbers of patients with IBD, CD, and UC without coexisting sarcoidosis, respectively. IBD/sarcoidosis patients were an average of 54.5 years old, of which 64.8% were female, 60.6% were Caucasian, and the patients were mostly admitted to large (63.5%) and urban teaching (58.8%) hospitals with an average ECI score of 5. No statistical difference was found between the IBD/sarcoidosis and IBD alone groups in terms of patient demographics (age, gender, race), hospital characteristics (bed size and teaching status), and ECI score (Table 1). In the IBD/sarcoidosis group, 5.9% of patients received MV, 1% had prolonged MV, 3.4% patients received TPN, and 4.1% had CVC during hospitalization. Again, no difference was found for the above interventions when compared to IBD alone group. In‐hospital outcomes and multivariate analysis Interestingly, our analysis revealed lower rates of penetrating disease (1.8 vs 5.6%, P < 0.001) and colectomy (2.4 vs 4.9%, P < 0.05) in the IBD/sarcoidosis group compared with the IBD alone group. Not surprisingly, IBD/sarcoidosis was associated with a higher rate of respiratory failure (8.1 vs 4.5%, P < 0.05). Although we observed lower rates of hospital mortality (1.4 vs 2%, P = 0.34), malnutrition (4.1 vs 5.6%, P = 0.15), stricturing disease/bowel obstruction (6.6 vs 8.8%, P = 0.09), and ileostomy (1.3 vs 2.4%, P = 0.09) in the IBD/sarcoidosis patient cohort, these results were not statistically significant. In addition, there was no difference in the rates of septic shock, acute renal failure, and hospitalization burden in terms of LOS or total hospitalization charges found between the IBD/sarcoidosis and IBD alone groups. Upon multivariate analysis (Table 2), patients with IBD/sarcoidosis were observed to have a significantly higher rate of respiratory failure (adjusted odds ratio [aOR] 2.05, 95% confidence interval [CI] 1.34–3.14, P < 0.001) compared to patients with IBD alone. In terms of IBD‐specific complications, IBD/sarcoidosis was independently associated with a significantly lower rate of penetrating disease (aOR 0.3, 95% CI 0.16–0.55, P < 0.0001) compared to IBD alone. In addition, IBD/sarcoidosis was also associated with a lower rate of colectomy (aOR 0.48, 95% CI 0.27–0.84, P < 0.05) when compared to IBD alone. Interestingly, after adjusting for confounders, we found higher total hospitalization charges (adjusted coefficient 7730.91, 95% CI 155.31–15 306.5, P < 0.05) in the IBD/sarcoidosis group when compared to the IBD alone group. Table 2 Multivariate regression analysis of outcomes for hospitalized patients with inflammatory bowel disease with and without coexisting sarcoidosis Outcomes Unadjusted odds ratio or coefficient (95% confidence interval) P‐value Adjusted odds ratio or coefficient (95% confidence interval) † P‐value In‐hospital mortality 0.68 (0.48, 0.97) 0.031 0.77 (0.34, 1.73) 0.53 Septic shock 0.95 (0.71, 1.26) 0.71 0.99 (0.52, 1.86) 0.96 Acute renal failure 0.95 (0.83, 1.08) 0.41 1.01 (0.75, 1.35) 0.96 Respiratory failure 1.88 (1.56, 2.26) <0.0001 2.05 (1.34, 3.14) 0.0009 Malnutrition 0.72 (0.59, 0.89) 0.0019 0.73 (0.46,1.16) 0.18 Penetrating disease 0.3 (0.23, 0.39) <0.0001 0.3 (0.16, 0.55) <0.0001 Stricturing disease/bowel obstruction 0.74 (0.63, 0.87) 0.00037 0.74 (0.51, 1.07) 0.11 Colectomy 0.47 (0.37, 0.61) <0.0001 0.48 (0.27, 0.84) 0.0099 Ileostomy 0.52 (0.37, 0.73) 0.00021 0.53 (0.24, 1.16) 0.11 Length of stay (days) 0.4 (−0.24, 1.04) 0.22 0.51 (−0.14, 1.15) 0.12 Total hospitalization charges (dollars) 5716.64 (−1884.59, 133 317.88) 0.14 7730.91 (155.31, 15 306.5) 0.045 † Adjusted for age, gender, race, primary insurance payer, hospital type, hospital bed size, income quartile, and Elixhauser Comorbidity Index score. Subgroup analysis Subsequent comparisons between CD/sarcoidosis and CD and UC/sarcoidosis and UC were performed. Compared to CD alone, CD/sarcoidosis had comparable demographic characteristics in terms of age, gender, and race (Table 3). No difference was found in hospital type, hospital teaching status, or ECI score between the CD/sarcoidosis and CD alone groups. Regarding interventions during hospitalization in the CD/sarcoidosis group, 4.4% patients received MV, 0.8% had prolonged MV, 3.4% patients received TPN, and 4.1% had CVC. There was no difference in intervention between the CD/sarcoidosis and the CD groups. In‐hospital outcomes analysis revealed lower rates of penetrating disease (2.8 vs 9%, P < 0.0001) and colectomy (1.6 vs 3.8%, P < 0.05) in the CD/sarcoidosis group compared to the CD alone group. After adjusting for confounders, this result remained significant for less penetrating disease (aOR 0.29, 95% CI 0.15–0.53, P < 0.0001) and colectomy (aOR 0.42, 95% CI 0.18–0.96, P < 0.05) in patients with CD/sarcoidosis. (Table 4). Table 3 Comparison of selected variables of patients hospitalized with Crohn's disease (CD) with and without coexisting sarcoidosis Variable CD with sarcoidosis CD without sarcoidosis P‐value N (weighted) n = 2500 n = 2500 Age 53.3 ± 0.8 54.9 ± 0.7 0.11 ECI score 4.1 ± 0.5 4.5 ± 0.4 0.50 Length of stay (days) 5.6 ± 0.3 5.2 ± 0.3 0.33 Total hospitalization charges (dollars) 42 376.5 ± 3350.4 36 729.4 ± 1919.1 0.14 Female 1725 (69) 1665 (62.3) 0.34 Caucasian 1450 (58) 1515 (60.6) 0.09 Large hospital bed 1520 (60.8) 1545 (61.8) 0.76 Urban teaching hospital 1445 (57.8) 1570 (62.8) 0.063 Medicare 1145 (45.8) 1225 (49) 0.81 Routine disposition 1765 (70.7) 1690 (67.6) 0.58 Mechanical ventilation 110 (4.4) 105 (4.2) 0.88 Prolonged mechanical ventilation 20 (0.8) 20 (0.8) 1.00 Total parenteral nutrition 85 (3.4) 105 (4.2) 0.53 Central venous catheterization 75 (3) 105 (4.2) 0.31 In‐hospital mortality 30 (1.2) 40 (1.6) 0.60 Septic shock 40 (1.6) 40 (1.6) 1.00 Acute renal failure 310 (12.4) 335 (13.4) 0.62 Respiratory failure 160 (6.4) 110 (4.4) 0.17 Malnutrition 90 (3.6) 150 (6) 0.059 Penetrating disease 70 (2.8) 225 (9) <0.0001 Stricturing disease/bowel obstruction 265 (10.6) 350 (14) 0.08 Colectomy 40 (1.6) 95 (3.8) 0.0268 Ileostomy 10 (0.4) 10 (0.4) 1.00 Values were reported as weighted means ± standard errors and weighted numbers (%). ECI, Elixhauser Comorbidity Index. Table 4 Multivariate regression analysis of outcomes for hospitalized patients with Crohn's disease with and without coexisting sarcoidosis Outcomes Unadjusted odds ratio or coefficient (95% confidence interval) P‐value Adjusted odds ratio or coefficient (95% confidence interval)† P‐value In‐hospital mortality 0.75 (0.46, 1.21) 0.23 0.88 (0.29, 2.67) 0.82 Septic shock 1 (0.64, 1.56) 1.00 1.04 (0.39, 2.79) 0.93 Acute renal failure 0.91 (0.78, 1.08) 0.29 0.99 (0.67, 1.44) 0.94 Respiratory failure 1.49 (1.16, 1.91) 0.0019 1.66 (0.94, 2.93) 0.08 Malnutrition 0.59 (0.45, 0.76) 0.0001 0.59 (0.32,1.08) 0.09 Penetrating disease 0.29 (0.22, 0.38) <0.0001 0.29 (0.15, 0.53) <0.0001 Stricturing disease/bowel obstruction 0.73 (0.61, 0.86) 0.0003 0.73 (0.5, 1.07) 0.11 Colectomy 0.41 (0.28, 0.6) <0.0001 0.42 (0.18, 0.96) 0.041 Ileostomy 1 (0.42, 2.41) 1.00 1.19 (0.18, 7.83) 0.85 Length of stay (days) 0.4 (−0.36, 1.17) 0.30 0.53 (−0.24, 1.3) 0.18 Total hospitalization charges (dollars) 5647.09 (−2014.33, 13 308.51) 0.15 7509.88 (−163.86, 15 183.62) 0.055 † Adjusted for age, gender, race, primary insurance payer, hospital type, hospital bed size, income quartile, and Elixhauser Comorbidity Index score. There was no significant difference with regard to age, gender, race, hospital type, hospital teaching status, and ECI score between the UC/sarcoidosis and UC alone groups (Table 5). In the UC/sarcoidosis group, 8.4% patients received MV, of which 1.3% had prolonged MV. 3.3% had TPN, and 6% received CVC. These intervention rates were not significantly different between the UC/sarcoidosis and the UC alone groups. UC/sarcoidosis was associated with a significantly higher rate of respiratory failure (11 vs 4.7%, P = 0.0025) compared to UC alone. After adjusting for confounders (Table 6), UC/sarcoidosis continued to have a higher rate of respiratory failure (aOR 2.66, 95% CI 1.39–5.1, P = 0.0031) when compared to UC alone. Multivariate regression analysis also showed a lower rate of colectomy (aOR 0.53, 95% CI 0.38–0.75, P = 0.0003) in the UC/sarcoidosis group when compared to the UC alone group. Table 5 Comparison of selected variables of patients hospitalized with ulcerative colitis (UC) with and without coexisting sarcoidosis Variable UC with sarcoidosis UC without sarcoidosis P‐value N (weighted) n = 1495 n = 1495 Age 56.5 ± 0.8 56.1 ± 1 0.75 ECI score 6.5 ± 0.6 6.1 ± 0.5 0.59 Length of stay (days) 6.4 ± 0.5 6 ± 0.4 0.53 Total hospitalization charges (dollars) 58 220.7 ± 5878 62 428.6 ± 5180.5 0.51 Female 865 (57.9) 825 (55.2) 0.48 Caucasian 970 (64.9) 950 (63.5) 0.79 Large hospital bed 1015 (67.9) 1090 (72.9) 0.31 Urban teaching hospital 905 (60.5) 930 (62.2) 0.57 Medicare 620 (41.5) 685 (45.8) 0.72 Routine disposition 965 (64.5) 1000 (66.9) 0.31 Mechanical ventilation 125 (8.4) 75 (5) 0.081 Prolonged mechanical ventilation 20 (1.3) 45 (3) 0.10 Total parenteral nutrition 50 (3.3) 45 (3) 0.79 Central venous catheterization 90 (6) 60 (4) 0.25 In‐hospital mortality 25 (1.7) 40 (2.7) 0.35 Septic shock 55 (3.7) 60 (4) 0.82 Acute renal failure 220 (14.7) 220 (14.7) 1.00 Respiratory failure 165 (11) 70 (4.7) 0.0025 Malnutrition 75 (5) 75 (5) 1.00 Colectomy 55 (3.7) 100 (6.7) 0.10 Ileostomy 40 (2.7) 85 (5.7) 0.065 Values were reported as weighted means ± standard errors and weighted numbers (%). ECI, Elixhauser Comorbidity Index. Table 6 Multivariate regression analysis of outcomes for hospitalized patients with ulcerative colitis with and without coexisting sarcoidosis Outcomes Unadjusted odds ratio or coefficient (95% confidence interval) P‐value Adjusted odds ratio or coefficient (95% confidence interval)† P‐value In‐hospital mortality 0.62 (0.37, 1.02) 0.062 0.65 (0.2, 2.1) 0.47 Septic shock 0.91 (0.63, 1.33) 0.63 0.92 (0.4, 2.13) 0.85 Acute renal failure 1 (0.82, 1.22) 1.00 1.05 (0.65, 1.68) 0.85 Respiratory failure 2.53 (1.89, 3.37) <0.0001 2.66 (1.39, 5.1) 0.0031 Malnutrition 1 (0.72, 1.39) 1.00 1 (0.47, 2.11) 1.00 Colectomy 0.53 (0.38, 0.75) 0.0003 0.53 (0.38, 0.75) 0.0003 Ileostomy 0.46 (0.31, 0.67) <0.0001 0.44 (0.18, 1.04) 0.061 Length of stay (days) 0.39 (−0.76, 1.54) 0.50 0.44 (−0.71, 1.6) 0.45 Total hospitalization charges (dollars) 5792.13 (−9845.59, 21 429.85) 0.47 7356.44 (−8326.58, 23 039.46) 0.36 † Adjusted for age, gender, race, primary insurance payer, hospital type, hospital bed size, income quartile, and Elixhauser Comorbidity Index score. Discussion This nationwide study examined the in‐hospital outcomes of patients with IBD/sarcoidosis compared to IBD alone. Subsequent subgroup analysis further compared CD/sarcoidosis versus CD alone and UC/sarcoidosis versus UC alone. The major findings were that IBD/sarcoidosis was associated with a significantly lower rate of penetrating disease, fewer colectomies, and a higher rate of respiratory failure compared to IBD alone. Subgroup analysis further specified that both CD/sarcoidosis and UC/sarcoidosis demonstrated lower risk of colectomy when compared to CD and UC alone, respectively. UC/sarcoidosis was particularly associated with a higher rate of respiratory failure. The association of sarcoidosis with less penetrating disease and colectomy in IBD patients is incompletely understood and not previously reported. Here, we propose several hypotheses to explain this finding. First, this finding may suggest that the coexistence of sarcoidosis impacts disease subphenotype in IBD. It has been accepted that the location of IBD is clearly associated with different risks of complications. 37 In CD, four subphenotypes have been classified based on location, with three exclusive subphenotypes (pure ileal disease, pure colonic disease, and ileocolonic disease) plus a fourth modifying subphenotype that may coexist with the three main subphenotypes: upper gastro‐intestinal tract location. 38 Ileal involvement (pure ileal disease and ileoclonic disease), which comprises around 60% of CD at diagnosis, 39 , 40 has been associated with developing strictures and/or fistulas 40 , 41 , 42 and therefore leads to the increased risk of surgery, 42 , 43 whereas left‐sided colonic CD is associated with a significant reduction in the risk of complications. 44 In UC, the subphenotype at diagnosis is generally split equally between proctitis, left‐sided disease, and pancolitis. 45 Extensive colitis in UC has been associated with an increased risk of colectomy. 46 Taken together, it is reasonable to hypothesize that the coexistence of sarcoidosis in IBD is associated with less ileal involvement in CD and less pancolitis in UC and possibly more left‐sided localized disease. These dominant subphenotypes carry lower risks of penetrating disease and colectomy. In fact, it was well documented that, when IBD coexists with certain other diseases (i.e. primary sclerosing cholangitis), the phenotype can be completely shifted to nonstricture‐forming and nonpenetrating colonic disease. 47 , 48 Similarly, sarcoidosis may play a role in determining the subphenotypes of IBD as well. The pathogenesis of ileal versus colonic CD has been extensively studied. ATG16L risk alleles, IL‐23/Th17 axis, αE+ T‐cells, and microbial community profiles in different key pathways have been shown to be significantly different between ileal and colonic CD. 49 One important allele potentially related to sarcoidosis is the caspase recruitment domain‐containing protein 15 (CARD15) gene polymorphisms. CARD15 is associated with ileal CD. 50 It has also been reported that early‐onset cases of sarcoidosis had heterozygous missense mutations in the CARD15 gene. 51 Moreover, an association between two CARD15 polymorphisms and specific sarcoidosis phenotypes have been demonstrated. 52 Whether sarcoidosis plays a role in the pathogenesis of a particular IBD subphenotype through the CARD15 pathway remains an intriguing possibility. No conclusion has been made thus far. Second, aside from dominant location subphenotypes of IBD, the phenotype of endoscopic lesions (i.e. the size and depth of ulcers) has also likely been of important clinical significance 53 in determining the rates of penetrating disease and subsequent surgery. Intestinal sarcoidosis is usually limited to the mucosa, whereas the inflammation in CD can be transmural. 54 An additional hypothesis for the low rates of penetrating disease and colectomy in CD patients is that sarcoidosis may be associated with more superficial mucosal lesions when coexisting with CD. Further endoscopic investigation on the size and depth of mucosal lesions in IBD/sarcoidosis patients is needed. In addition, a changing pattern of disease behavior has been described in IBD. 55 On diagnosis of CD, most patients exhibit purely inflammatory behavior (nonstricturing, nonpenetrating). Ten years later, approximately one‐third of the patients were seen to have developed stricturing and another third fistulating disease. 56 For patients with UC, approximately 50% of initial proctitis or left‐sided colitis spreads over time. 57 It is likely that patients with coexisting IBD and sarcoidosis present with more clinically apparent symptoms and are more likely be admitted to the hospital at an early stage of IBD. Therefore, not many patients would have developed penetrating disease or experienced colectomy at the time of their admission. As expected, our study revealed a high rate of respiratory failure in patients with IBD/sarcoidosis compared to the IBD alone group. It is well accepted that more than 90% of patients with sarcoidosis have evidence of intrathoracic involvement. 58 It has also been reported that a patient's immunogenic background could underlie the heterogeneity of sarcoidosis and play a role in the clinical manifestation of the disease. 59 The underlying lung disease may explain the high rate of respiratory failure during hospitalization. Although associated with higher rates of respiratory failure, there was no difference in MV or prolonged MV observed between the IBD/sarcoidosis and IBD only groups. This result may suggest that IBD is associated with a treatment‐sensitive phenotype of pulmonary sarcoidosis. This study has several strengths. As a nationwide sample, the NIS database provided a large sample size to study the IBD/sarcoidosis population. Therefore, our results are based on a high‐power study and provide a national review of the disease. To the best of our knowledge, this is a leading study to evaluate the clinical outcomes of patients with coexisting IBD and sarcoidosis. Identification of significant clinical outcomes associated with the immunopathological and genetic association of IBD and sarcoidosis may aid in making decisions regarding diagnosis and treatment. Our study also has limitations. All diagnoses are dependent on the accuracy of ICD‐9 codes, for which validation is routinely performed by the Agency for Healthcare Research and Quality, although coding errors may compromise the quality of the data. This study's main diagnostic ICD‐9‐CM codes for IBD and sarcoidosis have been previously used and validated in different studies. 29 , 30 , 33 An additional inherent limitation of the NIS database is that no laboratory values, images, or pharmacological interventions are recorded. Therefore, additional information that may help better identify disease activity and stage are not available. Future studies will be needed to address this information during the investigation of both IBD and sarcoidosis that are featured by a dynamic and heterogenic clinical picture. In conclusion, this national study used a large dataset from the United States to examine the in‐hospital outcomes of IBD/sarcoidosis. Our results first identified that sarcoidosis is associated with unique clinical features when coexisting with IBD, including lower risk of penetrating disease and colectomy compared to IBD alone. Furthermore, we strengthened the previous understanding of pulmonary sarcoidosis, leading to significant respiratory complications for hospitalized patients. These results may suggest a specific clinical and pathological subphenotype of IBD when coexisting with sarcoidosis. Prospective studies at the genetic and clinicopathological levels will assist in gaining a better understanding of the mechanism of the interaction between IBD and sarcoidosis. Ultimately, more diagnostic and therapeutic strategies are expected. Supporting information Table S1 ICD‐9‐CM codes. Click here for additional data file. Acknowledgments The authors thank Dr Chunyi Wu for her assistance with statistical analysis. ==== Refs References 1 Cho JH . The genetics and immunopathogenesis of inflammatory bowel disease . Nat. Rev. Immunol. 2008 ; 8 : 458 –66 .18500230 2 Iannuzzi MC . Advances in the genetics of sarcoidosis . Proc. Am. Thorac. Soc. 2007 ; 4 : 457 –60 .17684289 3 Jostins L , Ripke S , Weersma RK et al Host‐microbe interactions have shaped the genetic architecture of inflammatory bowel disease . Nature . 2012 ; 491 : 119 –24 .23128233 4 Newman LS , Rose CS , Bresnitz EA et al A case control etiologic study of sarcoidosis: environmental and occupational risk factors . Am. J. Respir. Crit. Care Med. 2004 ; 170 : 1324 –30 .15347561 5 Sostegni R , Daperno M , Pera A . Pulmonary manifestations of inflammatory bowel disease . Dig. Liver Dis. 2007 ; 39 : 239 –41 .17267308 6 Tunc B , Filik L , Bilgic F , Arda K , Ulker A . Pulmonary function tests, high‐resolution computed tomography findings and inflammatory bowel disease . Acta Gastroenterol. Belg. 2006 ; 69 : 255 –60 .17168120 7 Orchard TR , Chua CN , Ahmad T , Cheng H , Welsh KI , Jewell DP . Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes . Gastroenterology . 2002 ; 123 : 714 –8 .12198697 8 Baughman RP , Teirstein AS , Judson MA et al Clinical characteristics of patients in a case control study of sarcoidosis . Am. J. Respir. Crit. Care Med. 2001 ; 164 (10 Pt 1 ): 1885 –9 .11734441 9 Mana J , Rubio‐Rivas M , Villalba N et al Multidisciplinary approach and long‐term follow‐up in a series of 640 consecutive patients with sarcoidosis: cohort study of a 40‐year clinical experience at a tertiary referral center in Barcelona, Spain . Medicine (Baltimore) . 2017 ; 96 : e7595.28723801 10 Higenbottam T , Cochrane GM , Clark TJ , Turner D , Millis R , Seymour W . Bronchial disease in ulcerative colitis . Thorax . 1980 ; 35 : 581 –5 .7444824 11 Mayock RL , Bertrand P , Morrison CE , Scott JH . Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature . Am. J. Med. 1963 ; 35 : 67 –89 .14046006 12 Brito‐Zeron P , Bari K , Baughman RP , Ramos‐Casals M . Sarcoidosis involving the gastrointestinal tract: diagnostic and therapeutic management . Am. J. Gastroenterol. 2019 ; 114 : 1238 –47 .30865014 13 Storch I , Rosoff L , Katz S . Sarcoidosis and inflammatory bowel disease . J. Clin. Gastroenterol. 2001 ; 33 : 345 .11588558 14 Mitchell DN , Rees RJ . Sarcoidosis and Crohn's disease . Proc. R. Soc. Med. 1971 ; 64 : 944 –6 .5114301 15 Bewig B , Manske I , Bottcher H , Bastian A , Nitsche R , Folsch UR . Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage . Respiration . 1999 ; 66 : 467 –9 .10516546 16 Wallaert B , Colombel JF , Tonnel AB et al Evidence of lymphocyte alveolitis in Crohn's disease . Chest . 1985 ; 87 : 363 –7 .3971763 17 Bonniere P , Wallaert B , Cortot A et al Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies . Gut . 1986 ; 27 : 919 –25 .3015749 18 Xavier RJ , Podolsky DK . Unravelling the pathogenesis of inflammatory bowel disease . Nature . 2007 ; 448 : 427 –34 .17653185 19 Song Z , Marzilli L , Greenlee BM et al Mycobacterial catalase‐peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis . J. Exp. Med. 2005 ; 201 : 755 –67 .15753209 20 Jarrot PA , Dury S , Rakotomalala A et al Association of sarcoidosis and ulcerative colitis: a review of 20 cases . Sarcoidosis Vasc. Diffuse Lung Dis. 2013 ; 30 : 212 –6 .24284294 21 Fok KC , Ng WW , Henderson CJ , Connor SJ . Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab . J. Crohns Colitis . 2012 ; 6 : 708 –12 .22398084 22 Hayashi T , Nakamura T , Kurachi K et al Ulcerative colitis accompanied with sarcoidosis and dermatomyositis: report of a case . Dis. Colon Rectum . 2008 ; 51 : 474 –6 .18224374 23 Nilubol N , Taub PJ , Venturero M , Lichtiger S , Bauer JJ . Ulcerative colitis and sarcoidosis . Mt. Sinai J. Med. 2001 ; 68 : 400 –2 .11687869 24 Halling ML , Kjeldsen J , Knudsen T , Nielsen J , Hansen LK . Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases . World J. Gastroenterol. 2017 ; 23 : 6137 –46 .28970729 25 Franke A , Fischer A , Nothnagel M et al Genome‐wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2 . Gastroenterology . 2008 ; 135 : 1207 –15 .18723019 26 Fischer A , Nothnagel M , Franke A et al Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes . Eur. Respir. J. 2011 ; 37 : 610 –6 .20650992 27 Cerri S , du Bois RM , Spagnolo P . Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? Eur. Respir. J. 2011 ; 37 : 489 –91 .21357923 28 Obi K , Hinton A , Sobotka L , Levine E , Conwell D , Zhang C . Hospital‐acquired conditions are associated with worse outcomes in crohn's disease‐related hospitalizations . Dig. Dis. Sci. 2017 ; 62 : 1621 –7 .28401424 29 Ananthakrishnan AN , McGinley EL , Binion DG , Saeian K . A novel risk score to stratify severity of Crohn's disease hospitalizations . Am. J. Gastroenterol. 2010 ; 105 : 1799 –807 .20216534 30 Ananthakrishnan AN , McGinley EL , Binion DG , Saeian K . Simple score to identify colectomy risk in ulcerative colitis hospitalizations . Inflamm. Bowel Dis. 2010 ; 16 : 1532 –40 .20091926 31 Agency for Healthcare Research and Quality R, MD . HCUP NIS Database Documentation. Healthcare Cost and Utilization Project (HCUP), 2019 [Cited 31 Jan. 2019]. Available from URL: www.hcup-usahrqgov/db/nation/nis/nisdbdocumentationjsp. 32 Xu F , Liu Y , Wheaton AG , Rabarison KM , Croft JB . Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States . Appl. Health Econ. Health Policy . 2019 ; 17 : 77 –91 .30259396 33 Ungprasert P , Wijarnpreecha K , Cheungpasitporn W , Thongprayoon C , Manatsathit W , Kroner PT . Inpatient prevalence, expenditures, and comorbidities of sarcoidosis: nationwide inpatient sample 2013‐2014 . Lung . 2019 ; 197 : 165 –71 .30798420 34 Moore BJ , White S , Washington R , Coenen N , Elixhauser A . Identifying increased risk of readmission and in‐hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index . Med. Care . 2017 ; 55 : 698 –705 .28498196 35 Haukoos JS , Lewis RJ . The propensity score . JAMA . 2015 ; 314 : 1637 –8 .26501539 36 Dugoff EH , Schuler M , Stuart EA . Generalizing observational study results: applying propensity score methods to complex surveys . Health Serv. Res. 2014 ; 49 : 284 –303 .23855598 37 Louis E , Van Kemseke C , Reenaers C . Necessity of phenotypic classification of inflammatory bowel disease . Best Pract. Res. Clin. Gastroenterol. 2011 ; 25 (Suppl. 1 ): S2 –7 .21640927 38 Silverberg MS , Satsangi J , Ahmad T et al Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology . Can. J. Gastroenterol. 2005 ; 19 (Suppl. A ): 5A –36A . 39 Nuij VJ , Zelinkova Z , Rijk MC et al Phenotype of inflammatory bowel disease at diagnosis in The Netherlands: a population‐based inception cohort study (the Delta Cohort) . Inflamm. Bowel Dis. 2013 ; 19 : 2215 –22 .23835444 40 Thia KT , Sandborn WJ , Harmsen WS , Zinsmeister AR , Loftus EV Jr . Risk factors associated with progression to intestinal complications of Crohn's disease in a population‐based cohort . Gastroenterology . 2010 ; 139 : 1147 –55 .20637205 41 Louis E , Michel V , Hugot JP et al Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype . Gut . 2003 ; 52 : 552 –7 .12631668 42 Guizzetti L , Zou G , Khanna R et al Development of clinical prediction models for surgery and complications in Crohn's disease . J. Crohns Colitis . 2018 ; 12 : 167 –77 .29028958 43 Henckaerts L , Van Steen K , Verstreken I et al Genetic risk profiling and prediction of disease course in Crohn's disease patients . Clin. Gastroenterol. Hepatol. 2009 ; 7 : 972 –80 e2 .19422935 44 Siegel CA , Horton H , Siegel LS et al A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables . Aliment. Pharmacol. Ther. 2016 ; 43 : 262 –71 .26567467 45 Moum B , Vatn MH , Ekbom A et al Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990‐93. A prospective population‐based study. The Inflammatory Bowel South‐Eastern Norway (IBSEN) Study Group of Gastroenterologists . Scand J Gastroenterol. 1996 ; 31 : 362 –6 .8726304 46 Hoie O , Wolters FL , Riis L et al Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years . Gastroenterology . 2007 ; 132 : 507 –15 .17258717 47 Iny O , Yanai H , Matalon S et al Crohn's disease behavior and location is altered when associated with primary sclerosing cholangitis . Isr. Med. Assoc. J. 2018 ; 20 : 25 –9 .29658203 48 Boonstra K , van Erpecum KJ , van Nieuwkerk KM et al Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease . Inflamm. Bowel Dis. 2012 ; 18 : 2270 –6 .22407885 49 Dulai PS , Singh S , Vande Casteele N et al Should we divide Crohn's disease into ileum‐dominant and isolated colonic diseases? Clin. Gastroenterol. Hepatol. 2019 ; 17 : 2634 –43 .31009791 50 Brant SR , Picco MF , Achkar JP et al Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes . Inflamm. Bowel Dis. 2003 ; 9 : 281 –9 .14555911 51 Kanazawa N , Okafuji I , Kambe N et al Early‐onset sarcoidosis and CARD15 mutations with constitutive nuclear factor‐kappaB activation: common genetic etiology with Blau syndrome . Blood . 2005 ; 105 : 1195 –7 .15459013 52 Sato H , Williams HR , Spagnolo P et al CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis . Eur. Respir. J. 2010 ; 35 : 324 –30 .19679608 53 Allez M , Lemann M , Bonnet J , Cattan P , Jian R , Modigliani R . Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy . Am. J. Gastroenterol. 2002 ; 97 : 947 –53 .12003431 54 Stampfl DA , Grimm IS , Barbot DJ , Rosato FE , Gordon SJ . Sarcoidosis causing duodenal obstruction. Case report and review of gastrointestinal manifestations . Dig. Dis. Sci. 1990 ; 35 : 526 –32 .2180656 55 Cosnes J , Cattan S , Blain A et al Long‐term evolution of disease behavior of Crohn's disease . Inflamm. Bowel Dis. 2002 ; 8 : 244 –50 .12131607 56 Kelly JK , Preshaw RM . Origin of fistulas in Crohn's disease . J. Clin. Gastroenterol. 1989 ; 11 : 193 –6 .2738360 57 Langholz E , Munkholm P , Davidsen M , Nielsen OH , Binder V . Changes in extent of ulcerative colitis: a study on the course and prognostic factors . Scand. J. Gastroenterol. 1996 ; 31 : 260 –6 .8833356 58 Ungprasert P , Carmona EM , Utz JP , Ryu JH , Crowson CS , Matteson EL . Epidemiology of sarcoidosis 1946‐2013: a population‐based study . Mayo Clin Proc. 2016 ; 91 : 183 –8 .26727158 59 Baughman RP , Lower EE , du Bois RM . Sarcoidosis . Lancet . 2003 ; 361 : 1111 –8 .12672326